[Case reports of the treatment with tobramycin solution for inhalation in severe bronchiectasis patients continuous infection of Pseudomonas aeruginosa].
Aerosolized tobramycin has been frequently used in cystic fibrosis patients in order to directly deliver the antibiotic to the endobronchial site of infection. Recently, we experienced three cases of severe chronic bronchial infection of Pseudomonas aeruginosa treated by aerosolized tobramycin inhalation (TOBI). For two cases, we succeeded in improving the patient's medical condition, quality of life, and reduced the amount of sputum. We consider that TOBI should be useful for chronic bronchial infection by Pseudomonas aeruginosa in the case of a patient who does not respond to usual antibiotics via other routes. But further investigation is necessary to reveal clinical efficacy and safety in non-CF patients with bronchiectasis.
Nakamura
Shigeki
S
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences.
Yanagihara
Katsunori
K
Morinaga
Yoshitomo
Y
Ohno
Hideaki
H
Higashiyama
Yasuhito
Y
Miyazaki
Yoshitsugu
Y
Hirakata
Youichi
Y
Tashiro
Takayoshi
T
Kohno
Shigeru
S
D000280:Administration, Inhalation; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001987:Bronchiectasis / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy*; D012138:Respiratory Therapy; D014031:Tobramycin / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D014031:Tobramycin